dHMN-5A

GARS1 | 2003

What Is dHMN-5A?

dHMN-5A is a type of CMT caused by autosomal dominant mutations in the GARS1 gene. This gene provides instructions for making glycyl-tRNA synthetase, an enzyme that attaches the amino acid glycine to its transfer RNA during protein synthesis. Mutations in the GARS1 gene disrupt this function, leading to impaired nerve signal transmission.

dHMN-5A is autosomal dominant, meaning that just one of the gene’s two copies needs a mutation to cause this subtype.

Clinical Features

The age of symptom onset in dHMN-5A is variable, ranging from childhood to early adulthood. Unlike many forms of CMT, dHMN-5A predominantly affects the upper limbs, with weakness and atrophy of the hand muscles often appearing early. The lower limbs typically become involved as the disease progresses. As a distal hereditary motor neuropathy, dHMN-5A predominantly affects the motor nerves, with sensation typically preserved. Nerve conduction studies usually show somewhat slowed conduction velocities and reduced amplitudes, consistent with an axonal form of CMT.

dHMN-5A symptoms may include:

  • Weakness in the hands, often as an early feature
  • Muscle atrophy, particularly of the hand muscles
  • Weakness in the feet and lower legs
  • Difficulty with fine motor skills and manual dexterity
  • Brisk reflexes
  • Foot deformities, including high arches
  • Foot drop
  • Additional symptoms not listed here

Disease Course

dHMN-5A shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
dHMN-5A

Classification
dHMN/HMN

Neuropathy Type
Axonal

Inheritance Pattern
autosomal dominant

Genetic Context

HGNC-Approved Gene Symbol
GARS1

Gene Full Name
Glycyl-tRNA Synthetase 1

HGNC Gene Alias(es)
GARS

Chromosome
7p14.3

Zygosity of Responsible Variant
Heterozygous

Variant Mechanism
Toxic Gain of Function (GoF)

ClinVar Pathogenic Variants

View dHMN-5A ClinVar Variants

dHMN-5A OMIM Entry

dHMN-5A OMIM

GARS1 OMIM Entry

GARS1 OMIM

More Info

dHMN-5A Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Glycyl tRNA Synthetase Mutations in Charcot-Marie-Tooth Disease Type 2D and Distal Spinal Muscular Atrophy Type V

Authors

Antonellis, A., Ellsworth, R. E., Sambuughin, N., Puls, I., Abel, A., Lee-Lin, S. Q., Jordanova, A., Kremensky, I., Christodoulou, K., Middleton, L. T., Sivakumar, K., Ionasescu, V., Funalot, B., Vance, J. M., Goldfarb, L. G., Fischbeck, K. H., & Green, E. D.

Publication Date
May 1, 2003

Updated: July 18, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.


Illustrated cover graphic showing a split landform with branching directional arrows, two people with question marks above their heads, and the title ‘SORD Deficiency: Decoding This Newly Discovered and Confusing CMT Subtype.


CMT-SORD: What Is This Unique CMT Subtype?

CMT-SORD is a newly discovered CMT subtype driven by toxic sorbitol accumulation. This article explains how "SORD" works, why this subtype is different, and how it led to the fastest-moving therapeutic program in CMT history.